Clinical Trial Update: The Value of Botox-A for Management of Low Anterior Resection Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating botox-A for managing low anterior resection syndrome in rectal cancer patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low Anterior Resection Syndrome
• Rectal Cancer

Drugs mentioned

• Botox-A (onabotulinumtoxinA)

Snippet

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) | Conditions: Low Anterior Resection Syndrome, Rectal Cancer | Phase 2 | Status: COMPLETED